Cigna Rituximab (Rituxan & Biosimilars) prior authorization requirements (2026)
What Cigna generally requires to approve Rituximab (Rituxan & Biosimilars) (CPT J9312, Q5115, Q5119, Q5123), for Commercial plans. Yes. Cigna generally requires prior authorization for Rituximab (Rituxan & Biosimilars) (CPT J9312, Q5115, Q5119, Q5123).
Medical-necessity criteria Cigna generally applies
Prior authorization required; the preferred biosimilars Truxima, Riabni, and Ruxience must be tried before non-preferred Rituxan. RHEUMATOID ARTHRITIS initial (one course approved at a time): tried ONE conventional synthetic DMARD (methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine) for at least 3 months, OR a prior 3-month trial of at least one biologic (no step-back to a csDMARD required); not used concurrently with another biologic or a targeted synthetic DMARD; prescribed by or in consultation with a rheumatologist. Dosing: one course = up to two 1000 mg IV doses at least 2 weeks apart; re-treatment no sooner than every 16 weeks. After two or more courses, continuation requires a documented beneficial response (CDAI, DAS28-ESR/CRP, SDAI, RAPID-3, or PAS-II) or symptom improvement.
Diagnoses that commonly support medical necessity
ICD-10-CM diagnoses frequently associated with medical necessity for Rituximab (Rituxan & Biosimilars). Confirm the covered diagnosis list against the current Cigna policy.
Commonly required documentation
- Diagnosis
- documented csDMARD or prior-biologic trial
- specialist prescriber
- for re-treatment, interval and response documentation.
Situations to verify before submitting
Cigna may not cover Rituximab (Rituxan & Biosimilars) in these situations. Verify against the current policy rather than assuming a denial:
- Not used concurrently with another biologic or a targeted synthetic DMARD
- Rituximab products for any other non-oncology use are considered not medically necessary
How to submit
- Method: Cigna / Express Scripts prior authorization
- Portal: Cigna Provider (CHCP)
Source
Source: Cigna Coverage Policy IP0319 Rituximab Intravenous (Non-Oncology) (eff 2026-02-01). Codes J9312, Q5115, Q5119, Q5123. Cigna requires a rheumatologist and accepts one csDMARD OR one biologic (no mandatory TNF step). Last verified 2026-06-17.
Frequently asked questions
Does Cigna require prior authorization for Rituximab (Rituxan & Biosimilars)?
Yes. Cigna generally requires prior authorization for Rituximab (Rituxan & Biosimilars) (CPT J9312, Q5115, Q5119, Q5123).
What does Cigna require to approve Rituximab (Rituxan & Biosimilars)?
Prior authorization required; the preferred biosimilars Truxima, Riabni, and Ruxience must be tried before non-preferred Rituxan. RHEUMATOID ARTHRITIS initial (one course approved at a time): tried ONE conventional synthetic DMARD (methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine) for at least 3 months, OR a prior 3-month trial of at least one biologic (no step-back to a csDMARD req… Always confirm against the current Cigna policy.
How long does a Cigna prior authorization take?
Turnaround varies by plan and submission method. Check the Cigna portal for current timeframes.
Submitting Rituximab (Rituxan & Biosimilars) to Cigna?
Praxigen checks your clinical note against these criteria before you submit and drafts a policy-cited appeal if it is denied. You review and submit; nothing is sent automatically.